IL6 and neoplasm: Metformin also selectively acts against CSCs by targeting EMT, blocking the IL-6/STAT3 axis or decreasing EMT transcriptional factors, and by increasing tumor sensitivity against other current therapies [197, 283–287]; therefore, it has been included in clinical trials [288].